Why choose biosimilars now and in the future?

Biosimilars facilitate patient access, provide more affordable treatment options and encourage innovation1,2

The many advantages of biosimilars:

Lower cost

The development of biosimilars can create lower patient costs for treatment, which can lead to:

  • Increased uptake of high value biologics1,2
  • Reinvestment of cost savings in the development of new and innovative therapies1
  • Switching to biosimilars is saving health systems vast sums of money – a trend which is set to keep on increasing for the foreseeable future3
  • Improved patient care1 

Increased choice and access

Biosimilars can offer broader access to biological products for patients. This can lead to:

  • Additional treatment choices for patients and HCPs1,2
  • Increased access to treatment options not previously available1
  • More access for patients at earlier stages of the therapy cycle4
  • The potential to improve the lives of people all over the world3

Encouraging innovation 

The development of biosimilars can create a more progressive, competitive environment, encouraging investment in the development of new biologic products. This can lead to:

  • Innovation among reference product manufacturers1 
  • Increased patient access to biosimilars and the most modern medicines1,2
  • Increased uptake of high value biologics1,2
  • Reinvestment of cost savings in the development of new and innovative therapies1
  • Improved patient care1


Why choose our biosimilars? Learn here


References
1. IMS Institute 2016. Delivering on the potential of biosimilar medicines. Available at: https://www.medicinesforeurope.com/wp-content/uploads/2016/03/IMS-Institute-Biosimilar-Report-March-2016-FINAL.pdf (Accessed February 2019). 2. IMS Health 2016. The impact of biosimilar competition. Available at: https://www.medicinesforeurope.com/wp-content/uploads/2016/08/IMS-Impact-of-Biosimilar-Competition-2016.pdf (Accessed February 2019). 3. Deloitte. The cost-effectiveness of biosimilars: Delivering value for money from pharma spending. Available at: https://blogs.deloitte.co.uk/health/2019/09/the-cost-effectiveness-of-biosimilars-delivering-value-for-money-from-pharma-spending.html (Accessed December 2020). 4. The Biosimilars Council. The benefits of biosimilars. Available at: https://biosimilarscouncil.org/wp-content/uploads/2018/01/Module-5.pdf (Accessed December 2020).